Risk Factors and Outcomes of Patients Colonized with KPC and NDM Carbapenemase-Producing Enterobacterales
Abstract
:1. Introduction
2. Results
3. Discussion
4. Materials and Methods
4.1. Study Design
4.2. Study Population
4.3. Measures
4.4. Microbiological Analysis
4.5. Statistical Analysis
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Tangden, T.; Giske, C.G. Global Dissemination of Extensively Drug-Resistant Carbapenemase-Producing Enterobacteriaceae: Clinical perspective on Detection, Treatment and Infection Control. J. Intern. Med. 2015, 277, 501–512. [Google Scholar] [CrossRef] [PubMed]
- Borer, A.; Saidel-Odes, L.; Riesenberg, K.; Eskira, S.; Peled, N.; Nativ, R.; Schlaeffer, F.; Sherf, M. Attributable mortality of carbapenem resistant Klebsiella pneumoniae bacteremia. Infect. Control Hosp. Epidemiol. 2009, 30, 972–976. [Google Scholar] [CrossRef] [PubMed]
- Albiger, B.; Glasner, C.; Struelens, M.J.; Grundmann, H.; Monnet, D.L.; the European Survey of Carbapenemase-Producing Enterobacteriaceae (EuSCAPE) working group. Carbapenemase-Producing Enterobacteriaceae in Europe: Assessment by national experts from 38 countries, May 2015. EuroSurveillance 2015, 20, 30062. [Google Scholar] [CrossRef] [PubMed]
- Segagni Lusignani, L.; Presterl, E.; Zatorska, B.; Nest, M.V.D.; Diab-Elschahawi, M. Infection control and risk factors for acquisition of carbapenemase-producing enterobacteriaceae. A 5 year (2011–2016) case-control study. Antimicrob. Resist. Infect. Control 2020, 9, 18. [Google Scholar] [CrossRef] [PubMed]
- Doi, Y.; Paterson, D.L. Carbapenemase-producing Enterobacteriaceae. Semin. Respir. Crit. Care Med. 2015, 36, 74–84. [Google Scholar]
- Tamma, P.D.; Huang, Y.; Opene, B.N.A.; Simner, P.J. Determining the Optimal Carbapenem MIC That Distinguishes Carbapenemase-Producing and Non- Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae. Antimicrob. Agents Chemother. 2016, 60, 6425–6429. [Google Scholar] [CrossRef] [PubMed]
- Vink, J.P.; Otter, J.A.; Edgeworth, J.D. Carbapenemase-producing Enterobacteriaceae—Once positive always positive? Curr. Opin. Gastroenterol. 2020, 36, 9–16. [Google Scholar] [CrossRef]
- Van Duin, D.; Doi, Y. The global epidemiology of carbapenemase-producing Enterobacteriaceae. Virulence 2017, 8, 460–469. [Google Scholar] [CrossRef]
- Ma, J.; Song, X.; Li, M.; Yu, Z.; Cheng, W.; Yu, Z.; Zhang, W.; Zhang, Y.; Shen, A.; Sun, H.; et al. Global spread of carbapenem resistant Enterobacteriaceae: Epidemiological features, resistance mechanisms, detection and therapy. Microbiol. Res. 2023, 266, 127249. [Google Scholar] [CrossRef]
- Navon-Venezia, S.; Leavitt, A.; Schwaber, M.J.; Rasheed, J.K.; Srinivasan, A.; Patel, J.B.; Carmeli, Y.; Israeli KPC Knp Study group. First report on a hyperepidemic clone of KPC3 producing Klebsiella pneumoniae in Israel genetically related to a strain causing outbreaks in the United States. Antimicrob. Agents Chemother. 2009, 53, 818–820. [Google Scholar] [CrossRef]
- Hussein, K.; Geffen, Y.; Eluk, O.; Warman, S.; Aboalheja, W.; Alon, T.; Firan, I.; Paul, M. The Changing Epidemiology of Carbapenemase-Producing Enterobacterales. Rambam Maimonides Med. J. 2022, 13, e0004. [Google Scholar] [CrossRef]
- Assis, R.; Lasnoy, M.; Adler, A. Clinical and epidemiological features of patients colonised by different types of carbapenemase-producing Enterobacterales. J. Glob. Antimicrob. Resist. 2021, 26, 108–113. [Google Scholar] [CrossRef]
- Borer, A.; Eskira, S.; Nativ, R.; Saidel-Odes, L.; Riesenberg, K.; Livshiz-Riven, I.; Schlaeffer, F.; Sherf, M.; Peled, N. A Multifaceted Intervention Strategy for an Eradication of a Hospital-Wide Outbreak caused by Carbapenem-resistant Klebsiella Pneumoniae in Southern Israel. Infect. Control Hosp. Epidemiol. 2011, 32, 1158–1165. [Google Scholar] [CrossRef]
- Kassem, A.; Raed, A.; Michael, T.; Sagi, O.; Shimoni, O.; Borer, A.; Saidel-Odes, L. Risk Factors and Outcome of Patients Colonized with Carbapenemase- Producing and Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae. Infect. Control Hosp. Epidemiol. 2020, 41, 1154–1161. [Google Scholar] [CrossRef]
- Park, S.H.; Yi, Y.; Suh, W.; Ji, S.K.; Han, E.; Shin, S. The impact of enhanced screening for carbapenemase-producing Enterobacterales in an acute care hospital in South Korea. Antimicrob. Resist. Infect. Control 2023, 12, 62. [Google Scholar] [CrossRef]
- Wu, W.; Feng, Y.; Tang, G.; Qiao, F.; McNally, A.; Zong, Z. NDM Metallo-β-Lactamases and Their Bacterial Producers in Health Care Settings. Clin. Microbiol. Rev. 2019, 32, e00115-18. [Google Scholar] [CrossRef]
- Jain, A.; Hopkins, K.L.; Turton, J.; Doumith, M.; Hill, R.; Loy, R.; Meunier, D.; Pike, R.; Livermore, D.M.; Woodford, N. NDM carbapenemases in the United Kingdom: An analysis of the first 250 cases. J. Antimicrob. Chemother. 2014, 69, 1777–1784. [Google Scholar] [CrossRef]
- Seo, H.; Kim, H.J.; Kim, M.J.; Chong, Y.P.; Kim, S.-H.; Lee, S.-O.; Choi, S.-H.; Kim, Y.S.; Woo, J.H.; Jung, J. Comparison of clinical outcomes of patients infected with KPC- and NDM-producing Enterobacterales: A retrospective cohort study. Clin. Microliol. Infect. 2021, 27, 1167.e1–1167.e8. [Google Scholar] [CrossRef]
- Karlowsky, J.A.; Lob, S.H.; Kazmierczak, K.M.; Badal, R.E.; Young, K.; Motyl, M.R.; Sahm, D.F. In Vitro Activity of Imipenem against Carbapenemase-Positive Enterobacteriaceae Isolates Collected by the SMART Global Surveillance Program from 2008 to 2014. J. Clin. Microbiol. 2017, 55, 1638–1649. [Google Scholar] [CrossRef]
- Castanheira, M.; Deshpande, L.M.; Mathai, D.; Bell, J.M.; Jones, R.N.; Mendes, R.E. Early dissemination of NDM-1 and OXA-181-producing Enterobacteriaceae in Indian hospitals: Report from the SENTRY Antimicrobial Surveillance Program, 2006–2007. Antimicrob. Agents Chemother. 2011, 55, 1274–1278. [Google Scholar] [CrossRef]
- Findlay, J.; Poirel, L.; Kessler, J.; Kronenberg, A.; Nordmann, P. New Delhi Metallo-β-Lactamase-Producing Enterobacterales Bacteria, Switzerland, 2019–2020. Eberging Infect. Dis. 2021, 27, 2628–2637. [Google Scholar] [CrossRef] [PubMed]
- Hernández-García, M.; Coque, T.M.; Gimeno, C.; González-Candelas, F. Characterization of carbapenemase-producing Enterobacteriaceae from colonized patients in a university hospital in Madrid, Spain, during the R-GNOSIS project depicts increased clonal diversity over time with maintenance of high-risk clones. J. Antimicrob. Chemother. 2018, 73, 3039–3043. [Google Scholar] [CrossRef] [PubMed]
- Kedišaletšea, M.; Phumuzile, D.; Angela, D.; Andrew, W.; Mae, N.F. Epidemiology, risk factors, and clinical outcomes of carbapenem-resistant Enterobacterales in Africa: A systematic review. J. Glob. Antimicrob. Resist. 2023, 35, 297–306. [Google Scholar] [CrossRef] [PubMed]
- Li, Y.; Ma, L.; Ding, X.; Zhang, R. Fecal carriage and genetic characteristics of carbapenem-resistant enterobacterales among adults from four provinces of China. Front. Epidemiol. 2024, 3, 1304324. [Google Scholar] [CrossRef]
- Arum, N.; Ghafur, A.; Kazi, M.; Rao, R.; Rodrigues, C.; Ratnamani, M.S.; Prathiba, J.; Alaparthi, S.; Gnanasoundari, P.; Premachandran, K.P.; et al. Prevalence of faecal carriage of Carbapenemase Producing Enterobacteriaceae in healthy Indian subjects from the community. Indian J. Med. Microbiol. 2022, 40, 374–377. [Google Scholar] [CrossRef]
Variable | KPC-CPE n = 92 | NDM-CPE n = 136 | p-Value | OR [95% CI] | |
---|---|---|---|---|---|
Age | mean ± SD | 67.2 ± 18.78 | 60.7 ± 19.56 | 0.013 | |
median (range) | 70.5 (19–94) | 65.5 (19–98) | |||
Male sex | 47 (51.1%) | 83 (61%) | |||
Origin | Home | 29 (31.5%) | 110 (80.9%) | 0.001 | 0.108 [0.05–0.2] |
Nursing home | 42 (45.7%) | 2 (1.5%) | <0.001 | 56.23 [13.13–241.2] | |
Other | 21 (22.8%) | 24 (17.6%) | 0.336 | ||
Department | Internal medicine | 75 (81.5%) | 83 (61%) | <0.001 | 2.81 [1.5–5.28] |
Surgery | 12 (13%) | 38 (27.9%) | 0.007 | 0.38 [0.19–0.79] | |
ICU | 3 (3.3%) | 8 (5.9%) | 0.364 | ||
Other | 2 (2.2%) | 7 (5.1%) | 0.258 | ||
Charlson Index | mean ± SD | 5.87 ± 3.28 | 4.18 ± 3.11 | <0.001 | |
median (range) | 6 (0–16) | 4 (0–13) | <0.001 | ||
Smoker | 21 (22.8%) | 36 (26.5%) | 0.640 | ||
Antibiotic treatment three months prior | 55 (59.8%) | 93 (68.4%) | 0.204 | ||
Steroid treatment three months prior | 16 (17.4%) | 29 (21.3%) | 0.502 | ||
Recurrent admission within six months | 58 (63%) | 96 (70.6%) | 0.251 |
Variable | KPC-CPE n = 92 | NDM-CPE n = 136 | p-Value | OR [95% CI] | ||
---|---|---|---|---|---|---|
Mechanical ventilation | 14 (15.2%) | 18 (13.2%) | 0.701 | |||
Hemodialysis | 6 (6.5%) | 11 (8.1%) | 0.799 | |||
Urinary catheter | 44 (47.8%) | 35 (25.7%) | 0.001 | 0.38 [0.22–0.66] | ||
Decubitus ulcer | 50 (54.9%) | 22 (16.2%) | <0.001 | 0.16 [0.09–0.29] | ||
Nosocomial CPE colonization | 29 (31.5%) | 55 (40.7%) | 0.165 | |||
Bacteria | Escherichia coli | 6 (6.5%) | 92 (67.6%) | <0.001 | 0.03 [0.001–0.08] | |
Klebsiella sp. | 63 (68.5%) | 17 (12.5%) | <0.001 | 15.2 [7.76–29.8] | ||
Enterobacter | 15 (16.3%) | 24 (17.6%) | 0.791 | |||
Other | 8 (8.7%) | 3 (2.3%) | 0.024 | 4.2 [1.1–16.3] | ||
Length of stay, days | Mean ± SD | 13.29 ± 17.16 | 10.1 ± 10.59 | 0.086 | ||
Median (range) | 6 (2–93) | 6 (2–59) | ||||
In-hospital mortality | 11 (12%) | 15 (11%) | 0.913 | |||
30-day post discharge mortality | 16 (18.4%) | 5 (4.2%) | 0.002 | 0.19 [0.07–0.55] | ||
Discharged to | Home | 25 (27.2%) | 103 (75.7%) | <0.001 | 0.11 [0.06–0.29] | |
Nursing home | 56 (60.9%) | 13 (9.6%) | <0.001 | 14.7 [7.24–29.9] |
Variable | p-Value | OR | 95% CI | |
---|---|---|---|---|
Lower | Upper | |||
Age < 65 | 0.620 | 1.254 | 0.512 | 3.068 |
Admission from home | 0.000 | 6.536 | 3.105 | 13.888 |
Charlson Index < 4 | 0.037 | 2.525 | 1.059 | 6.024 |
No urinary catheter | 0.034 | 2.164 | 1.058 | 4.426 |
No decubitus ulcer | 0.042 | 2.250 | 1.031 | 4.972 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Saidel-Odes, L.; Sagi, O.; Troib, S.; Leeman, H.; Nativ, R.; Schlaeffer-Yosef, T.; Azulay, H.; Nesher, L.; Borer, A. Risk Factors and Outcomes of Patients Colonized with KPC and NDM Carbapenemase-Producing Enterobacterales. Antibiotics 2024, 13, 427. https://doi.org/10.3390/antibiotics13050427
Saidel-Odes L, Sagi O, Troib S, Leeman H, Nativ R, Schlaeffer-Yosef T, Azulay H, Nesher L, Borer A. Risk Factors and Outcomes of Patients Colonized with KPC and NDM Carbapenemase-Producing Enterobacterales. Antibiotics. 2024; 13(5):427. https://doi.org/10.3390/antibiotics13050427
Chicago/Turabian StyleSaidel-Odes, Lisa, Orli Sagi, Shani Troib, Hannah Leeman, Ronit Nativ, Tal Schlaeffer-Yosef, Hovav Azulay, Lior Nesher, and Abraham Borer. 2024. "Risk Factors and Outcomes of Patients Colonized with KPC and NDM Carbapenemase-Producing Enterobacterales" Antibiotics 13, no. 5: 427. https://doi.org/10.3390/antibiotics13050427
APA StyleSaidel-Odes, L., Sagi, O., Troib, S., Leeman, H., Nativ, R., Schlaeffer-Yosef, T., Azulay, H., Nesher, L., & Borer, A. (2024). Risk Factors and Outcomes of Patients Colonized with KPC and NDM Carbapenemase-Producing Enterobacterales. Antibiotics, 13(5), 427. https://doi.org/10.3390/antibiotics13050427